Synaptogenix
About:
Synaptogenix is a clinical-stage biopharmaceutical company that develops novel therapies for neurodegenerative diseases.
Website: https://www.synaptogen.com
Twitter/X: synaptogenix
Top Investors: Bantam Group
Description:
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCϵ) activation, Bryostatin-1 stimulates synaptic growth factors, amyloid-β degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.
$68.4M
New York, New York, United States
2012-01-01
Daniel Alkon
1-10
2024-09-11
Public
© 2025 bioDAO.ai